Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for BOS after HCT
NCT03315741Phase 1Completed
- Sponsor
- Stanford University
- Start
- Mar 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pirfenidone in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Stanford University. Primary endpoint: Drug tolerability (maintaining recommended dose) at 52 weeks. Started Mar 2018; status: completed.
02
Drugs
pirfenidone
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT03315741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315741.